News : European Thrombosis and Haemostasis Alliance

Horizon Europe calls for proposals

Looking for funding opportunities? The following may be relevant to your science and research interests in the field of bleeding and clotting. For each one, you will find more information and the procedures to follow by clicking on ...

ETHA Statement on Lessons learned from COVID-19: the need fo...

On World Thrombosis Day 2022, the European Thrombosis and Haemostasis Alliance calls upon the European Parliament Special Committee on COVID-19 to take into account the importance of thrombosis when formulating lessons learned from ...

ETHA contributes to the EU Non-Communicable Diseases Initiat...

The European Thrombosis and Haemostasis Alliance (ETHA) is pleased to have suggested priorities for EU-funded health policy actions to the EU Healthier Together Non-Communicable Diseases Initiative. Our contribution touched on all f...

Statement from the International Society on Thrombosis and H...

Earlier this week, the European Medicines Agency (EMA) and UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) completed their assessments of extremely rare blood clotting events associated with low platelet counts tha...

European Thrombosis and Haemostasis Alliance Welcomes Europe...

18 March 2021 – The European Thrombosis and Haemostasis Alliance (ETHA) welcomes the European Medicines Agency’s (EMA) decision today following the recent reports of thrombotic events (blood clots) following COVID-19 vaccina...

Saving and Improving Lives by Addressing Cancer-Associated T...

Cancer-associated thrombosis (blood clots) is a leading cause of death in cancer patients. It affects patients of all cancer types, at all cancer stages. It is essential that the Europe’s Beating Cancer Plan and the EU Cancer Miss...